Multiple myeloma in younger patients: the role of age as prognostic factor
β Scribed by A. Corso; C. Klersy; M. Lazzarino; C. Bernasconi
- Publisher
- Springer
- Year
- 1998
- Tongue
- English
- Weight
- 161 KB
- Volume
- 76
- Category
- Article
- ISSN
- 0939-5555
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Serum [32-microglobulin , serum thymidine kinase, and commonly used prognostic parameters were investigated for their prognostic value in a well-defined group of patients with multiple myeloma (n = 207). Multivariate analysis showed hemoglobin to be the parameter of strongest prognostic value. Only
## Abstract Although multiple myeloma (MM) is predominantly a disease of the elderly, few studies have focused on the identification of prognostic factors in this group of patients. Four hundred twenty five MM patients >65 years were uniformly treated with chemotherapy (MP or VCMP/VBAD). Multivaria
## Background: The effect of interleukin-6 (il-6), the major growth factor for myeloma cells, may be enhanced by soluble il-6 receptor (sil-6r). therefore, the current study investigated the clinical significance of serum sil-6r in patients with multiple myeloma (mm). ## Methods: Serum levels of